Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07393334 · ClinicalTrials.gov registry record · Phase 2
Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive
A Phase 2 study of Male Contraception and Semen Volume, sponsored by Next Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07393334: Recruiting Phase 2 study of Male Contraception and Semen Volume, sponsored by Next Life Sciences.
NCT07393334 is a Phase 2 study of Male Contraception and Semen Volume that is actively recruiting participants, run by Next Life Sciences. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07393334, a Phase 2 study of Male Contraception and Semen Volume, is actively recruiting participants, sponsored by Next Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be randomized in a crossover design to receive a single dose of NLS-133, an active control or placebo either 90 or 180 minutes prior to collection of semen. Sperm parameters measured will be count, motility and morphology. A brief questionnaire will be completed by each subject during each treatment cycle that addresses orgasm and ejaculation quality. Safety monitoring will include adverse event reporting, laboratory assessments, and vital signs.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NLS-133
- DRUG Active Comparator #1
Study Locations (1)
Washington
- Population Center for Research in Human Reproduction and Departments of Medicine, University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT07393334 shows while recruiting
NCT07393334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Male Contraception appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07393334 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07393334 about?
NCT07393334 is a clinical study titled "Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive". NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be rand...
What is the current status of trial NCT07393334?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-12-02. Estimated completion is 2026-05.
What conditions does trial NCT07393334 study?
This clinical trial studies the following conditions: Male Contraception, Semen Volume, Sperm Motility.
What interventions are being tested in trial NCT07393334?
The interventions under investigation include: Placebo (DRUG), NLS-133 (DRUG), Active Comparator #1 (DRUG).
Who is sponsoring clinical trial NCT07393334?
This trial is sponsored by Next Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07393334 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07393334's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI